• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    More On ANP.AX



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Antisense Therapeutics Ltd. (ANP.AX)

    0.03 Up 0.00(6.25%) Apr 29, 1:46AM EDT
    ProfileGet Profile for:
    Antisense Therapeutics Ltd.
    6 - 8 Wallace Avenue
    Toorak, VIC 3142
    Australia - Map
    Phone: 61 3 9827 8999
    Fax: 61 3 9827 1166
    Website: http://www.antisense.com.au

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:8

    Business Summary 

    Antisense Therapeutics Ltd. engages in the research, development, and commercialization of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of insulin like growth factor 1 receptor to treat prostate cancer. Its product pipeline also includes ATL1103, a second generation antisense drug to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action. The company has a partnership with Isis Pharmaceuticals, Inc. for the discovery and development of antisense drugs. Antisense Therapeutics Ltd. is based in Toorak, Australia.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Antisense Therapeutics Ltd.

    Key Executives 
    Mr. Mark Diamond BSc, MBA, MAICD,
    Chief Exec. Officer, Managing Director and Director
    Mr. Phillip Allen Hains BBus(Acc), MBA, CA, 57
    Chief Financial Officer and Company Sec.
    Dr. George Tachas ,
    Director of Drug Discovery & Patents
    Susan Turner ,
    Exec. Officer
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in AUD.